Evan Jerrold Barnes, M.D.
Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Evan Barnes's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Evan Barnes has written about over time.
BiopsyCombined Modality TherapyDisease ManagementDisease SusceptibilityFatal OutcomeIn Situ Hybridization, FluorescenceLeukemiaOncogene Proteins, FusionProto-Oncogene Proteins c-bcrReceptor, Fibroblast Growth Factor, Type 1Sequence Analysis, DNATranslocation, GeneticCell LineDrug Resistance, NeoplasmFusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMutationProtein Kinase Inhibitors
To see the data from this visualization as text,
click here.
| Name | Number of Publications | First Publication Year | Most Recent Publication Year | Average Publication Date |
|---|
| Biopsy | 1 | 2020 | 2020 | March 2020 |
| Combined Modality Therapy | 1 | 2020 | 2020 | March 2020 |
| Disease Management | 1 | 2020 | 2020 | March 2020 |
| Disease Susceptibility | 1 | 2020 | 2020 | March 2020 |
| Fatal Outcome | 1 | 2020 | 2020 | March 2020 |
| In Situ Hybridization, Fluorescence | 1 | 2020 | 2020 | March 2020 |
| Leukemia | 1 | 2020 | 2020 | March 2020 |
| Oncogene Proteins, Fusion | 1 | 2020 | 2020 | March 2020 |
| Proto-Oncogene Proteins c-bcr | 1 | 2020 | 2020 | March 2020 |
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 2020 | March 2020 |
| Sequence Analysis, DNA | 1 | 2020 | 2020 | March 2020 |
| Translocation, Genetic | 1 | 2020 | 2020 | March 2020 |
| Cell Line | 1 | 2022 | 2022 | October 2022 |
| Drug Resistance, Neoplasm | 1 | 2022 | 2022 | October 2022 |
| Fusion Proteins, bcr-abl | 1 | 2022 | 2022 | October 2022 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 2022 | October 2022 |
| Mutation | 1 | 2022 | 2022 | October 2022 |
| Protein Kinase Inhibitors | 1 | 2022 | 2022 | October 2022 |